BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

952 related articles for article (PubMed ID: 15735043)

  • 21. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
    Kitazaki T; Oka M; Nakamura Y; Tsurutani J; Doi S; Yasunaga M; Takemura M; Yabuuchi H; Soda H; Kohno S
    Lung Cancer; 2005 Sep; 49(3):337-43. PubMed ID: 15955594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
    Katayama K; Shibata K; Mitsuhashi J; Noguchi K; Sugimoto Y
    Anticancer Res; 2009 Apr; 29(4):1059-65. PubMed ID: 19414346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
    Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
    Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y; Ishikawa E; Asada S; Sugimoto Y
    Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Perego P; De Cesare M; De Isabella P; Carenini N; Beggiolin G; Pezzoni G; Palumbo M; Tartaglia L; Pratesi G; Pisano C; Carminati P; Scheffer GL; Zunino F
    Cancer Res; 2001 Aug; 61(16):6034-7. PubMed ID: 11507048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
    Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
    Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
    Maliepaard M; van Gastelen MA; de Jong LA; Pluim D; van Waardenburg RC; Ruevekamp-Helmers MC; Floot BG; Schellens JH
    Cancer Res; 1999 Sep; 59(18):4559-63. PubMed ID: 10493507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
    Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
    Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
    Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.